Videos

Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.

Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.

Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about coming research involving immunotherapy for patients with lung cancer.

David A. Braun, MD, PhD continues the first-line clinical trial discussion with the addition of KEYNOTE-426 and CLEAR trial data.

Tian Zhang, MD, MHS, and Moshe Orenstein, MD, MA, recall data from two clinical trials for first-line treatment of advanced renal cell carcinoma: CheckMate-9ER and CheckMate-214.

A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.

Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.

Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy.

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

Zofia Piotrowska, MD, shares insight on testing strategies for EGFR Exon 20 insertions, and which patients should be tested for these alterations.

Zofia Piotrowska, MD, provides an overview of EGFR mutations in advanced NSCLC, including EGFR Exon 20 insertions, and their clinical significance in patients with advanced NSCLC.

Dr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.

Recommendations for how to best treat patients with EGFR-mutated non–small cell lung cancer when there are discrepancies between clinical trial data and real-world evidence.

A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.

Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.

Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis

Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about the findings of the DESTINY-Lung01 study that were presented at 2021 ESMO.

Resources that can help educate patients and community physicians about the risk for chronic graft-vs-host disease post-transplantation.

Risk factors associated with chronic graft-vs-host disease, and insight regarding how the condition commonly presents in patients.

Clinicians discuss how they treat patients with steroid-refractory acute graft-vs-host disease and consider where ruxolitinib fits into the therapeutic landscape.

A panel of clinicians review the case of a patient with acute graft-vs-host disease and share how they typically approach similar scenarios.

Potential implications of ongoing studies evaluating tipifarnib for patients with HRAS-mutated head and neck squamous cell carcinoma.

Drs Liliana Bustamante and Richard Kim react to limitations surrounding biomarkers used in colorectal cancer and consider how to best study the role of ctDNA moving forward.

An expert explains PARP inhibitor use in the metastatic prostate cancer treatment landscape and typical adverse events seen during therapies.